{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-005988","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.388116+00:00","generated_at":"2026-05-26T03:40:42.776655+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board","bullets":["KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.","Ended 2024 with $820.4M cash; repaid $50M Pharmakon loan in Nov 2024.","Advanced PRAME pipeline: Phase 3 PRISM-MEL-301 enrolled first patient; IMC-P115C and IMC-R117C first doses in Phase 1.","Appointed Dr. William Pao (CEO of Revelio Therapeutics) as non-executive director effective Feb 25, 2025.","Expects to present initial HIV data (IMC-M113V) in Q1 2025 and HBV data (IMC-I109V) in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-005988","json":"https://secwatch.observer/filing/0001140361-25-005988.json","markdown":"https://secwatch.observer/filing/0001140361-25-005988.md","text":"https://secwatch.observer/filing/0001140361-25-005988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/0001140361-25-005988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/ef20044296_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:40:42.776655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1d299203e","claim":"William Pao was appointed as Director at Immunocore Holdings plc.","evidence_excerpt":"the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/0001140361-25-005988-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}